PMID- 29050517
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20171227
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 17
IP  - 1
DP  - 2018 Jan
TI  - The safety and efficacy of dabrafenib and trametinib for the treatment of 
      melanoma.
PG  - 73-87
LID - 10.1080/14740338.2018.1390562 [doi]
AB  - The introduction of BRAF and MEK inhibitors into clinical practice improved the 
      prognosis of metastatic melanoma patients. The combination of BRAF inhibitor 
      dabrafenib with MEK inhibitor trametinib has shown its superiority to single 
      agent therapy and is characterized by a tolerable spectrum of adverse events 
      which shows a decrease in incidence over time on treatment. Areas covered: The 
      current scientific literature on safety and adverse events (AEs) related to BRAF 
      and MEK-inhibition has been investigated with special focus on the large phase 3 
      studies (COMBI-v, COMBI-d and CoBRIM) as well as recent updates presented at 
      oncology and melanoma meetings. Additionally, published case series/case reports 
      were screened for information on AEs. Expert opinion: Even though almost every 
      patient (98%) under combination therapy with dabrafenib and trametinib 
      experiences at least one adverse event, these are generally mild to moderate, 
      reversible and can be managed with dose reductions or interruptions. However, due 
      to an increased life expectancy, there is a substantial need to prevent and treat 
      also mild adverse events, as they play a central role for the quality of life of 
      patients. Ongoing clinical trials will have to demonstrate the efficacy as well 
      as safety of triple combination with anti-PD-1/anti-PD-L1 antibodies.
FAU - Knispel, Sarah
AU  - Knispel S
AD  - a Skin Cancer Unit, Department of Dermatology , University Hospital Essen, 
      University of Duisburg-Essen , Essen , Germany.
FAU - Zimmer, Lisa
AU  - Zimmer L
AD  - a Skin Cancer Unit, Department of Dermatology , University Hospital Essen, 
      University of Duisburg-Essen , Essen , Germany.
FAU - Kanaki, Theodora
AU  - Kanaki T
AD  - a Skin Cancer Unit, Department of Dermatology , University Hospital Essen, 
      University of Duisburg-Essen , Essen , Germany.
FAU - Ugurel, Selma
AU  - Ugurel S
AD  - a Skin Cancer Unit, Department of Dermatology , University Hospital Essen, 
      University of Duisburg-Essen , Essen , Germany.
FAU - Schadendorf, Dirk
AU  - Schadendorf D
AD  - a Skin Cancer Unit, Department of Dermatology , University Hospital Essen, 
      University of Duisburg-Essen , Essen , Germany.
FAU - Livingstone, Elisabeth
AU  - Livingstone E
AD  - a Skin Cancer Unit, Department of Dermatology , University Hospital Essen, 
      University of Duisburg-Essen , Essen , Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171020
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Imidazoles)
RN  - 0 (Oximes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 33E86K87QN (trametinib)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Imidazoles/administration & dosage
MH  - Melanoma/*drug therapy/pathology
MH  - Oximes/administration & dosage
MH  - Prognosis
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/pharmacology
MH  - Pyridones/administration & dosage
MH  - Pyrimidinones/administration & dosage
MH  - Quality of Life
MH  - Skin Neoplasms/*drug therapy/pathology
OTO - NOTNLM
OT  - Adverse events
OT  - BRAF
OT  - MEK
OT  - dabrafenib
OT  - melanoma
OT  - trametinib
EDAT- 2017/10/21 06:00
MHDA- 2017/12/28 06:00
CRDT- 2017/10/21 06:00
PHST- 2017/10/21 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
PHST- 2017/10/21 06:00 [entrez]
AID - 10.1080/14740338.2018.1390562 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2018 Jan;17(1):73-87. doi: 10.1080/14740338.2018.1390562. 
      Epub 2017 Oct 20.